Is NCT06563505 recruiting in Houston, TX?

Yes, NCT06563505 is currently recruiting participants at its Houston, TX location. This lymphoma clinical trial is actively enrolling qualified participants.

How do I join the lymphoma clinical trial in Houston?

To join this clinical trial in Houston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Houston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Lymphoma Clinical Trial in Houston, TX

Who Can Participate

Inclusion Criteria

Patients must meet the following criteria for study entry:

Histologically diagnosed marginal zone lymphoma (any subtypes) o Low grade or indolent B-cell lymphoma unclassifiable is also eligible

Have received at least 1 prior treatment including CD20 monoclonal antibody

Patients have relapsed or refractory disease to their most recent regimen

Stage II, III or IV disease

Age ≥18 years. Because no dosing or adverse event data are currently available on the use of mosunetuzumab and zanubrutinib combination in patients \<18 years of age, children are excluded from this study.

Performance status ≤2 on the ECOG scale (≤3 if due to lymphoma)

Requiring systemic therapy assessed by investigator based on tumor size, symptoms and/or GELF criteria

A nodal or extranodal (except spleen) mass \> 7 cm in its greater diameter

At least 3 nodal or extranodal sites ≥ 3 cm in diameter

Presence of at least one B symptom

Fever (\>38 C), night sweats, weight loss \> 10% in the past 6 months

Symptomatic splenomegaly (or size \>13cm)

Impending organ compression or involvement (ureteral, orbital, gastrointestinal)

Any of the following cytopenias due to bone marrow involvement of lymphoma

Hemoglobin ≤ 10 g/dL

Platelets ≤ 100 x 109/L

Absolute neutrophil count (ANC) \< 1.5x109/L

Pleural effusion or ascites

LDH \> ULN or β2 microglobulin \> ULN

Bi-dimensionally measurable disease, with at least one nodal lesion ≥ 1.5 cm or one extra-nodal lesion \> 1 cm in longest diameter by CT, PET/CT, and/or MRI

Subjects with splenic MZL who do not meet the radiographically measurable disease criteria are eligible for participation if spleen is enlarged over 16 cm and MZL is histologically confirmed by bone marrow biopsy or peripheral blood flow cytometry

Subjects with EMZL such as skin of conjunctival EMZL who do not meet the radiographically measurable disease criteria are eligible for participation if at least one of the skin lesions is histologically confirmed as MZL and measures ≥1.5 cm in diameter

Patients must have adequate organ and marrow function as defined below:

Total bilirubin ≤ 1.5 institutional ULN, unless consistent with Gilbert's (ratio between total and direct bilirubin \> 5)

AST (SGOT) and ALT (SGPT) ≤ 3 x institutional ULN

Alkaline phosphatase \< 2.5 ULN

Creatinine clearance ≥ 40 ml/min calculated by modified Cockcroft-Gault formula

Blood counts below if without lymphoma cause for cytopenia

Hemoglobin ≥ 8 g/dL

Platelets ≥ 75 x 109/L

Absolute neutrophil count (ANC) ≥ 1.0x109/L

Blood counts below if cytopenia are due to lymphoma (such as bone marrow involvement or splenomegaly)

Hemoglobin ≥ 6 g/dL (no transfusion within 7 days prior to treatment)

Platelets ≥ 50 x 109/L

Absolute neutrophil count (ANC) ≥ 0.5x109/L

Exclusion Criteria

Subjects will be ineligible for this study if they meet any of following criteria:

Known active central nervous system lymphoma or leptomeningeal disease.

Treatment with any chemotherapeutic agent, or treatment with any other anti-lymphoma agent (investigational or otherwise) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to first investigational agent administration.

Any prior history of other malignancy besides B-NHL, unless the patient has been free of disease for ≥ 3 years and felt to be at low risk for recurrence by the treating physician, except:

Adequately treated localized skin cancer without evidence of disease.

Adequately treated cervical carcinoma in situ without evidence of disease.

Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of lenalidomide capsules, or put the study outcomes at undue risk.

Uncontrolled human immunodeficiency virus (HIV), or active Hepatitis C Virus, or active Hepatitis B Virus infection, or any uncontrolled active significant infection, including suspected or confirmed JC virus infection and SARS-CoV2.

Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HBsAg) positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded. Subjects with a history of Hepatitis C who received antiviral treatment are eligible as long as PCR is negative.

History of immunodeficiency (with the exception of hypogammaglobulinemia) or concurrent systemic immunosuppressant therapy (e.g., cyclosporine, tacrolimus, etc., or chronic administration glucocorticoid equivalent of \>10mg/day of prednisone) within 28 days of the first dose of study drug with exception of steroid used for IV contrast allergy. In addition, use of inhaled, topical, intranasal corticosteroids or local steroid injection (eg, intra- articular injection) is permitted.

Use of strong/moderate inhibitors within 7 days or 5 half-lives prior to the first dose of zanubrutinib; usage of strong/moderate CYP3A inducers within 14 days prior to the first dose of zanubrutinib.

Requiring ongoing therapy with strong or moderate CYP3A inducers.

Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study.

Significant screening electrocardiogram (ECG) abnormalities including 2nd degree atrioventricular (AV) block, type II AV block, or 3rd degree block.

Active bleeding or known bleeding diathesis (e.g., von Willebrand's disease) or hemophilia.

History of stroke or intracranial hemorrhage within 6 months prior to study entry.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT06563505) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lymphoma Treatment Options in Houston, TX

If you're searching for lymphoma treatment options in Houston, TX, this clinical trial (NCT06563505) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lymphoma clinical trials near you to find additional studies recruiting in your area.

Lymphoma Clinical Trial in Houston, TX

Expert Care in Houston

IRB Approved

No-Cost Care

Apply for This Houston Location

Why Participate?

Simple Process

About This Lymphoma Study in Houston